As new Alzheimer’s biomarkers come into play, here’s where the money is going

With two anti-amyloid Alzheimer’s disease drugs on the market, investors are on the hunt for the next big thing. After a slow start on the market, venture capitalists are now directing more funding toward new tests and biomarkers that could boost treatment and prevention.